Retaglutide

$1,000.00

Out of stock

Category: Tag:
Happy Dolly - by , September 30, 201
4/ 5stars
I just got what i was looking for for a long time and good price
Impressed of a good service - by , December 25, 2019
5/ 5stars
Realy almost frustrated to find this product from a reliable source. Now i know where to buy.

Description

Retaglutide for weight control

Product Name: Retatrutide (Research Grade)
Catalog ID: RETA-001
Formulation: Lyophilized Powder (Sterile Filtered)
Purity: ≥98% (determined by HPLC)
Molecular Weight: ~4.5 kDa (subject to salt/water content)
Sequence: [Redacted for proprietary research]


Product Overview
Retatrutide is a synthetic, linear peptide engineered for advanced preclinical investigation. It is uniquely designed as a unimolecular tri-agonist, targeting three key metabolic receptors: the Glucose-dependent Insulinotropic Polypeptide receptor (GIPR), the Glucagon-like Peptide-1 receptor (GLP-1R), and the Glucagon receptor (GCGR). This multi-receptor activation profile distinguishes it from traditional single- or dual-agonist analogs, offering a broad mechanistic platform for studying integrated metabolic signaling pathways.

Key Research Applications

  • Metabolic Pathway Mapping: Investigate the synergistic effects of simultaneous GIP, GLP-1, and glucagon receptor modulation on lipid and glucose metabolism in vitro and in vivo.

  • Energy Homeostasis Studies: Examine the compound’s influence on caloric utilization and substrate oxidation in preclinical metabolic models.

  • Adipose Tissue Research: Study the direct and indirect effects of triple-receptor agonism on adipocyte differentiation, lipolysis, and thermogenic gene expression.

  • Comparative Pharmacology: Serve as a reference standard for benchmarking the efficacy and receptor-binding kinetics of novel experimental peptides.

Physical & Chemical Characteristics

  • Appearance: White to off-white lyophilized cake or powder.

  • Solubility: Readily soluble in sterile water for injection (WFI), 0.9% saline solution, or standard phosphate-buffered saline (PBS) at a pH range of 4.0–5.5. For optimal reconstitution, it is recommended to gently swirl the vial without vigorous shaking.

  • Storage Conditions: Store lyophilized material at -20°C, protected from light. Upon reconstitution, aliquot and store at -80°C for long-term stability. Avoid repeated freeze-thaw cycles.

  • Stability: Stable for 24 months in lyophilized form when stored under recommended conditions.

Quality Assurance
This product is supplied for research purposes only and undergoes rigorous quality control testing to ensure batch-to-batch consistency. Each lot is tested for:

  • Identity: Confirmed by Mass Spectrometry (MS).

  • Purity: Assessed by Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC).

  • Content: Quantified by UV absorbance at 280 nm.

  • Endotoxin Level: <1.0 EU/mg.

Handling & Reconstitution Protocol (Suggested)

  1. Equilibrate the sealed vial to room temperature to prevent condensation.

  2. Reconstitute with an appropriate volume of sterile diluent to achieve the desired stock concentration (e.g., 5–10 mg/mL).

  3. Gently swirl the vial until the solution is clear and free of visible particulates.

  4. Use immediately or aliquot for single-use experiments to maintain peptide integrity.

Usage Disclaimer
This product is offered exclusively for in vitro testing, laboratory experimentation, and scientific research conducted by qualified professionals. It is not intended for diagnostic procedures, therapeutic applications, or human or veterinary administration of any kind. This material is sold as a chemical reagent and must be handled with appropriate personal protective equipment (PPE) in a controlled laboratory environment.


Ordering Information
Available in standard research quantities (2 mg, 5 mg, and 10 mg vials). Bulk and custom synthesis inquiries are available upon request for large-scale preclinical studies.

Reviews

There are no reviews yet.

Be the first to review “Retaglutide”

Your email address will not be published. Required fields are marked *